利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

137 records (took 0.034 seconds)

    CELL-TARGETING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES
    1.
    发明申请
    CELL-TARGETING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES 有权

    公开(公告)号：US20220401568A1

    公开(公告)日：2022-12-22

    申请号：US17459133

    申请日：2021-08-27

    Applicant: Molecular Templates, Inc.

    Inventor： Eric Poma ,  Erin Willert ,  Jason Kim

    IPC: A61K47/64 ,  C07K16/28 ,  C07K16/30 ,  A61K47/68 ,  C07K16/32 ,  C07K14/25 ,  A61K39/12 ,  A61K39/00

    Abstract: The present invention provides cell-targeting molecules which can deliver a CD8+ T-cell epitope cargo to the MHC class I presentation pathway of the cell. The cell-targeting molecules of the invention can be used to deliver virtually any CD8+ T-cell epitope from an extracellular space to the MHC class I pathway of a target cell, which may be a malignant cell and/or non-immune cell. The target cell can then display on a cell-surface the delivered CD8+ T-cell epitope complexed with MHC I molecule. The cell-targeting molecules of the invention have uses which include the targeted labeling and/or killing of specific cell-types within a mixture of cell-types, including within a chordate, as well as the stimulation of beneficial immune responses. The cell-targeting molecules of the invention have uses, e.g., in the treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections.

    MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES
    3.
    发明申请
    MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES 有权

    公开(公告)号：US20220306701A1

    公开(公告)日：2022-09-29

    申请号：US17705619

    申请日：2022-03-28

    Applicant: Molecular Templates, Inc.

    Inventor： Eric POMA ,  Erin WILLERT

    IPC: C07K14/25 ,  C07K14/245 ,  C12N9/10 ,  C12N9/24 ,  C12N15/62 ,  C07K16/00 ,  C07K16/08 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32

    Abstract: The present invention is directed to T-cell epitope delivering polypeptides which deliver one or more CD8+ T-cell epitopes to the MHC class I presentation pathway of a cell, including toxin-derived polypeptides which comprise embedded T-cell epitopes and are de-immunized. The present invention provides cell-targeted, CD8+ T-cell epitope delivering molecules for the targeted delivery of cytotoxicity to certain cells, e.g., infected or malignant cells, for the targeted killing of specific cell types, and the treatment of a variety of diseases, disorders, and conditions, including cancers, immune disorders, and microbial infections. The present invention also provides methods of generating polypeptides capable of delivering one or more heterologous T-cell epitopes to the MHC class I presentation pathway, including polypeptides which are 1) B-cell and/or CD4+ T-cell de-immunized, 2) comprise embedded T-cell epitopes, and/or 3) comprises toxin effectors which retain toxin functions.

    OPTIMIZED CELL-FREE SYNTHESIS OF INVASION PLASMID ANTIGEN B AND RELATED COMPOSITIONS AND METHODS OF USE
    4.
    发明申请
    OPTIMIZED CELL-FREE SYNTHESIS OF INVASION PLASMID ANTIGEN B AND RELATED COMPOSITIONS AND METHODS OF USE 有权

    公开(公告)号：US20220125907A1

    公开(公告)日：2022-04-28

    申请号：US17492190

    申请日：2021-10-01

    Applicant: Vaxcyte, Inc.

    Inventor： Neeraj KAPOOR ,  Jeffery C. FAIRMAN

    IPC: A61K39/112 ,  A61P31/04 ,  C07K14/25

    Abstract: The present disclosure provides a cell-free method for synthesizing an Invasion Plasmid Antigen B (IpaB) antigen associated with a Shigella bacterium comprising exogenous addition of the purified chaperone protein IpgC to the cell-free synthesis mixture. The disclosure further provides IpaB antigen mutants comprising non-natural amino acids incorporated during cell-free synthesis, enabling covalent conjugation to a Shigella O-antigen polysaccharide. Further provided are Ipa B antigens and conjugates thereof, as well as immunogenic compositions prepared with the synthesized IpaB antigens and conjugates thereof and methods of use.

    Multivalent CD20-binding molecules comprising Shiga toxin a subunit effector regions and enriched compositions thereof
    5.
    发明授权
    Multivalent CD20-binding molecules comprising Shiga toxin a subunit effector regions and enriched compositions thereof 有权

    公开(公告)号：US11104707B2

    公开(公告)日：2021-08-31

    申请号：US16515829

    申请日：2019-07-18

    Applicant: Molecular Templates, Inc.

    Inventor： Eric Poma ,  Erin Willert ,  Jason Kim ,  Jack Higgins ,  Jensing Liu ,  Rodney Flores-Lefranc

    IPC: C07K14/25 ,  C07K16/28 ,  A61P35/02

    Abstract: The present invention provides multivalent CD20-binding molecules and compositions thereof, such as enriched compositions comprising large proportions of multivalent CD20-binding molecules relative to monovalent CD20-binding molecules. Certain multivalent CD20-binding molecules of the present invention comprise (i) two or more CD20-binding regions and (ii) one or more Shiga toxin effector polypeptide regions derived from an A Subunit of a member of the Shiga toxin family. Certain multivalent CD20-binding molecules of the present invention, and compositions thereof, have uses for selective killing of specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, tumors, and immune disorders. Certain multivalent CD20-binding molecules of the present invention, and compositions thereof, have uses for delivering agents into CD20-expressing cells, collecting diagnostic information, and monitoring the treatment of a variety of diseases, such as cancers, tumors, and immune disorders which involve CD20-expressing cells.

    PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS
    6.
    发明申请
    PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS 有权

    公开(公告)号：US20210079097A1

    公开(公告)日：2021-03-18

    申请号：US17025729

    申请日：2020-09-18

    Applicant: Molecular Templates, Inc.

    Inventor： Eric Poma ,  Hilario Ramos ,  Erin Willert ,  Richard Shimkets ,  Crystal Jackson ,  Thomas Vincent

    IPC: C07K16/28 ,  C07K14/25 ,  A61P35/00

    Abstract: Provided herein are PD-L1 binding molecules comprising or conjugated to a toxin, e.g. a Shiga toxin A Subunit derived polypeptide. In some embodiments, the PD-L1 binding molecules are cytotoxic. In some embodiments, the PD-L1 binding molecules are capable of delivering a CD8+ T-cell epitope to an MHC class molecule inside a PD-L1 positive cell. The PD-L1 binding molecules described herein have uses for selectively killing specific cells (e.g., PD-L1 positive tumor cells and/or immune cells); for selectively delivering cargos to specific cells (e.g., PD-L1 positive tumor cells or immune cells), and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers and tumors involving PD-L1 expressing cells (e.g., PD-L1 positive tumor cells or immune cells).

    MHC Class I Epitope Delivering Polypeptides
    10.
    发明申请
    MHC Class I Epitope Delivering Polypeptides 审中-公开

    公开(公告)号：US20190153044A1

    公开(公告)日：2019-05-23

    申请号：US16220468

    申请日：2018-12-14

    Applicant: MOLECULAR TEMPLATES, INC.

    Inventor： ERIC POMA ,  ERIN WILLERT

    IPC: C07K14/25 ,  C07K16/28 ,  C12N9/10 ,  C12N9/24 ,  C12N15/62 ,  C07K14/245 ,  C07K16/08 ,  C07K16/10 ,  C07K16/32 ,  C07K16/00

    Abstract: The present invention is directed to T-cell epitope delivering polypeptides which deliver one or more CD8+ T-cell epitopes to the MHC class I presentation pathway of a cell, including toxin-derived polypeptides which comprise embedded T-cell epitopes and are de-immunized. The present invention provides cell-targeted, CD8+ T-cell epitope delivering molecules for the targeted delivery of cytotoxicity to certain cells, e.g., infected or malignant cells, for the targeted killing of specific cell types, and the treatment of a variety of diseases, disorders, and conditions, including cancers, immune disorders, and microbial infections. The present invention also provides methods of generating polypeptides capable of delivering one or more heterologous T-cell epitopes to the MHC class I presentation pathway, including polypeptides which are 1) B-cell and/or CD4+ T-cell de-immunized, 2) comprise embedded T-cell epitopes, and/or 3) comprises toxin effectors which retain toxin functions.

Patent Agency Ranking